The Medical Letter on Drugs and Therapeutics
Issue 1527
Safety of Long-Term PPI Use; Sarilumab (Kevzara) for Rheumatoid Arthritis; Cardiovascular Effects of Some Antidiabetic Drugs; Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only); In Brief: Midostaurin (Rydapt) for AML and Advanced Systemic Mastocytosis (online only)
The full issue is available to subscribers Subscriber Login   
Safety of Long-Term PPI Use

Proton pump inhibitors (PPIs), which are used for treatment of gastroesophageal reflux disease (GERD) and for prevention of upper gastrointestinal adverse effects caused by NSAIDs and aspirin, are one of the most commonly prescribed classes of drugs in the US. All PPIs are similarly effective and generally well tolerated,1,2 but their long-term use has been associated with a number of safety concerns.3,4 Recommendations addressing these concerns have recently been published.5,6

FRACTURES — The labels of all prescription PPIs include a warning about an increased risk of fractures with long-term use.7

Mechanism – Reduced gastric acidity might interfere with calcium absorption.

Clinical Studies – A meta-analysis of 18 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1527
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35